IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals
October 25, 2012

IOTA scientists publish on fragment based drug discovery for T. brucei phosphodiesterases
A paper by IOTA scientists Anitha Shanmugham, Paul England and David Bailey, with collaborators from the VU University in Amsterdam, entitled “Catechol Pyrazolinones as Trypanocidals: Fragment-Based Design, Synthesis, and Pharmacological Evaluation of Nanomolar Inhibitors of Trypanosomal Phosphodiesterase B1” has been published in J. Medicinal Chemistry. The paper describes the discovery of novel T. brucei PDE inhibitors using a combination of T. brucei genome analysis, in silico modeling, virtual screening and fragment docking, coupled with biochemical screening for fragment efficacy. The paper illustrates the powerful synergies between design and screening in fragment-based drug discovery for neglected parasitic diseases.